HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Related Collections Related Article Social Bookmarking                What's this?

Influenza and Pneumococcal Immunization in Diabetes

Abbreviations: ACIP, Advisory Committee on Immunization Practices

The first 20% of the full text of this article appears below.

	RATIONALE FOR IMMUNIZATION

 
The rationale for the use of influenza and pneumococcal vaccine in patients with diabetes is reviewed in the American Diabetes Association technical review "Use of Influenza and Pneumococcal Vaccine in People with Diabetes" (1) and can be summarized as follows:

• Patients with diabetes may have abnormalities in immune function and presumed increased morbidity and mortality from infection.
  
• Epidemiological studies support the fact that patients with diabetes (in particular those with end organ complications of cardiac and renal disease) are at high risk for complications, hospitalization, and death from influenza and pneumococcal disease.
  
• There is sufficient evidence that people with diabetes generally have appropriate humoral immune responses to vaccination.
  
• Subgroup analysis of patients with diabetes reported in clinical narrative and case-control studies support the fact that vaccination against influenza has been effective in reducing hospital admissions during influenza epidemics.
  
• Although the question of the efficacy of pneumococcal vaccination in preventing nonbacteremic disease remains unresolved, many studies have shown that the vaccine is effective in reducing life-threatening bacteremic disease.
  
• Immunization against influenza and pneumococcal disease is an important part of preventive services for many chronic diseases such as diabetes.
  

According to the Advisory Committee on Immunization Practices (ACIP), the American College of Physicians, the American Academy of Pediatrics, and the American Academy of Family Physicians, vaccinating individuals at high risk before influenza season each year is the most effective measure for reducing the impact of influenza (2). The effective implementation of immunization can reduce the cost of human suffering . . . [Full Text of this Article]

	INFLUENZA VACCINATION

 

	PNEUMOCOCCAL IMMUNIZATION

 

	CONCLUSIONS

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

POSITION STATEMENTS & ADA STATEMENTS
Diabetes Care 2006 29: S75-S77. [Extract] [Full Text] [PDF]